Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 SoligenixForward Pharma A/SCumberland PharmaceuticalsRegulus TherapeuticsAkari Therapeutics
SymbolNASDAQ:SNGXNASDAQ:FWPNASDAQ:CPIXNASDAQ:RGLSNASDAQ:AKTX
Price Information
Current Price$1.51$7.32$3.17$1.38$2.41
52 Week RangeBuyN/ABuyHoldBuy
MarketRank™
Overall Score1.40.70.90.91.4
Analysis Score3.30.00.01.23.5
Community Score2.92.82.22.92.7
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.80.00.8
Earnings & Valuation Score0.60.61.30.60.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyHoldBuy
Consensus Price Target$3.44N/AN/A$1.25$5.00
% Upside from Price Target127.65% upsideN/AN/A-9.42% downside107.47% upside
Trade Information
Market Cap$60.43 million$49.71 million$47.30 million$100.06 million$38.22 million
Beta1.421.850.322.411.52
Average Volume4,028,26465,25464,5203,092,655235,938
Sales & Book Value
Annual Revenue$4.60 millionN/A$47.53 million$6.83 millionN/A
Price / Sales13.14N/A1.0014.65N/A
CashflowN/AN/A$0.51 per shareN/AN/A
Price / CashN/AN/A6.25N/AN/A
Book Value$0.07 per share$11.42 per share$3.36 per share$0.95 per share($0.11) per share
Price / Book21.57N/A0.941.45N/A
Profitability
Net Income$-9,360,000.00$-4,220,000.00$-3,540,000.00$-18,590,000.00$-17,110,000.00
EPS($0.48)N/A$0.23($1.08)($0.93)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-567.04%N/A-8.36%N/AN/A
Return on Equity (ROE)-328.25%N/A3.86%-150.66%-880.38%
Return on Assets (ROA)-140.08%N/A1.92%-57.52%-161.52%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.02%N/A0.31%N/AN/A
Current Ratio2.30%118.57%2.04%1.35%1.55%
Quick Ratio2.30%N/A1.62%1.35%1.55%
Ownership Information
Institutional Ownership Percentage9.39%12.88%26.15%19.96%9.20%
Insider Ownership Percentage3.09%N/A39.72%18.24%61.80%
Miscellaneous
Employees155902410
Shares Outstanding40.02 million6.79 million14.92 million72.51 million15.86 million
Next Earnings Date5/21/2021 (Estimated)4/23/2021 (Estimated)5/19/2021 (Estimated)5/13/2021 (Estimated)6/4/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 50-Day Moving Average of $3.02Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 50-Day Moving Average of $3.02
americanbankingnews.com - April 6 at 2:58 AM
Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest UpdateAkari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update
americanbankingnews.com - March 28 at 3:30 AM
AKARI THERAPEUTICS PLC(AKTX)AKARI THERAPEUTICS PLC(AKTX)
fool.com - March 21 at 8:10 AM
Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Down 28.0% in FebruaryAkari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Down 28.0% in February
americanbankingnews.com - March 18 at 1:38 AM
Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Declines By 28.0%Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Declines By 28.0%
americanbankingnews.com - March 16 at 1:14 AM
BRIEF—Akari’s nomacopan to be studied in civilian and battlefield traumaBRIEF—Akari’s nomacopan to be studied in civilian and battlefield trauma
thepharmaletter.com - March 5 at 10:10 AM
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in TraumaAkari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
finance.yahoo.com - March 4 at 10:03 AM
Akari Therapeutics PASylated Nomacopan Shows Promising Action In Animal StudiesAkari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
finance.yahoo.com - February 25 at 8:25 PM
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting ...Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting ...
apnews.com - February 25 at 9:28 AM
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and UveitisAkari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
finance.yahoo.com - February 25 at 9:28 AM
Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders?Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders?
finance.yahoo.com - February 2 at 8:03 AM
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological DiseaseAkari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
finance.yahoo.com - February 1 at 9:47 AM
Akari Therapeutics to Participate in Two January Virtual Investor ConferencesAkari Therapeutics to Participate in Two January Virtual Investor Conferences
finance.yahoo.com - January 6 at 9:53 AM
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical ProgressAkari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
morningstar.com - December 11 at 10:32 AM
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
finance.yahoo.com - December 11 at 10:32 AM
Akari Therapeutics Reports Third Quarter 2020 Financial Results  and Highlights Recent Clinical ProgressAkari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
finance.yahoo.com - December 11 at 10:31 AM
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal DiseaseAkari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
finance.yahoo.com - December 3 at 6:17 PM
Akari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash WiselyAkari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash Wisely
finance.yahoo.com - December 1 at 8:11 AM
Akari Therapeutics PLC (ADR)Akari Therapeutics PLC (ADR)
reuters.com - November 15 at 11:51 PM
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy ...Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy ...
apnews.com - October 28 at 7:44 PM
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
finance.yahoo.com - October 27 at 1:07 PM
Akari Therapeutics Reports Continued Progress In COVID-19 Pneumonia Program With NomacopanAkari Therapeutics Reports Continued Progress In COVID-19 Pneumonia Program With Nomacopan
markets.businessinsider.com - October 6 at 9:34 AM
Akaris nomacopan to enter late-stage skin blistering disorder study during next yearAkari's nomacopan to enter late-stage skin blistering disorder study during next year
seekingalpha.com - October 1 at 2:42 PM
Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education ConferenceAkari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference
nasdaq.com - September 29 at 12:10 PM
Akari Therapeutics to Participate in Two September Virtual Investor ConferencesAkari Therapeutics to Participate in Two September Virtual Investor Conferences
finance.yahoo.com - September 10 at 9:19 AM
DateCompanyBrokerageAction
1/28/2021SoligenixB. RileyReiterated Rating
12/23/2020SoligenixAlliance Global PartnersLower Price Target
7/28/2020SoligenixDawson JamesDowngrade
6/25/2020SoligenixMaxim GroupInitiated Coverage
9/1/2020Regulus TherapeuticsHC WainwrightReiterated Rating
7/24/2020Regulus TherapeuticsWedbushReiterated Rating
5/15/2020Regulus TherapeuticsNeedham & Company LLCInitiated Coverage
3/19/2019Regulus TherapeuticsWells Fargo & CompanyLower Price Target
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.